Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

129 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2019-01-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to examine the potential benefits of vortioxetine in combination with at-home computerized cognitive training program to improve cognition, such as memory, attention, and concentration. This study will compare the effectiveness of vortioxetine plus cognitive training versus placebo plus cognitive training.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Investigate the Safety and Efficacy of NeuroQ on Cognitive Function in Health Adults with Self-Reported Memory Problems

NCT06672094

Healthy Self-reported Memory Problems

COMPLETED PHASE2

Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults

NCT06733714

Cognitive Dysfunction Alzheimer Disease Mild Cognitive Impairment +8 more

RECRUITING NA

Neurostimulation and Cognitive Intervention in Alzheimer's Disease

NCT02772185

Alzheimer's Disease

UNKNOWN PHASE2/PHASE3

Using Exercise and Electrical Brain Stimulation to Improve Memory in Dementia

NCT03670615

Mild Cognitive Impairment Alzheimer Disease

COMPLETED NA

Personalized Brain Stimulation for Cognitive Impairment in Older Adults

NCT07208734

Alzheimer s Disease

ENROLLING_BY_INVITATION NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this research study is to examine the potential benefits of vortioxetine in combination with at-home computerized cognitive training program to improve cognition, such as memory, attention, and concentration. This study will compare the effectiveness of vortioxetine plus cognitive training versus placebo plus cognitive training.

Vortioxetine is considered investigational when used as a treatment for age-related cognitive decline, which means that it has not been approved by the U.S. Food and Drug Administration for this purpose. Vortioxetine is approved by the U.S. Food and Drug Administration as a treatment for depression, and also goes by the name Trintellix (formerly known as Brintellix). That means that, while the drug itself is approved by the FDA, it is not approved for the reasons the investigators are using it in this study.

Participation in this study entails an estimated 6 study visits over the course of approximately six months. Participants will complete various assessments at our lab at the Washington University School of Medicine along with check-in visits in-person or over the phone. Additionally, they will participate in at home computerized cognitive training for approximately six months, supplemented with either vortioxetine or placebo.

The investigators will assess memory and problem-solving abilities using paper and pencil, computerized measures, and self-assessments of how participants feel. These tests could include numbers, letters, symbols, words, or sentences. These tests will be repeated throughout the study. If eligible to do so, participants will complete a baseline MRI scan.

A subset of participants who completed a baseline MRI scan will complete another MRI scan after approximately 26 weeks of vortioxetine or placebo and at home computerized cognitive training.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Age-related Cognitive Decline

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vortioxetine plus cognitive training

Vortioxetine (10 mg) plus cognitive training 5 times weekly for 30 minutes a day

Group Type EXPERIMENTAL

Vortioxetine 10 mg

Intervention Type DRUG

Cognitive training program

Intervention Type BEHAVIORAL

Online training program, 30 minutes a day, 5 times a week

Placebo plus cognitive training

Placebo plus cognitive training 5 times weekly for 30 minutes a day

Group Type PLACEBO_COMPARATOR

Cognitive training program

Intervention Type BEHAVIORAL

Online training program, 30 minutes a day, 5 times a week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vortioxetine 10 mg

Intervention Type DRUG

Cognitive training program

Online training program, 30 minutes a day, 5 times a week

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Trintellix

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Community-living men and women age 65 and older
* Age-related cognitive decline as defined by (a) self-reported cognitive dysfunction that is attributed to the aging process (in response to screening questions to the participant); (b) ability to complete cognitive battery, but still scoring less than 1 standard deviation above age-matched norms at both baseline and after the two-week cognitive training lead-in.

Exclusion Criteria

* Known dementia or other clinical neurodegenerative illness (e.g., Parkinson's disease, cerebrovascular disease) per self-report, informant report, medical records, or neuropsychological testing
* Any current psychiatric disorder
* Medical conditions that suggest shortened lifespan, such as metastatic cancer; or would prohibit safe participation in the interventions, including cardiovascular disease or musculoskeletal conditions; or with the assessments.
* Sensory impairment that would prevent participation
* IQ \< 70 as estimated by the Wechsler Test of Adult Reading
* Alcohol or substance abuse within 6 months
* Concurrent cognitive training, such as brain-training software, or other interventions expected to affect neuroplasticity
* Psychotropic medications or those with likely CNS effects (none within 4 weeks prior to study entry)

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes